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Aim: To investigate the qualitative aspects in patient selection and the quantitative impact of 
disease burden in real world treatment of vitreomacular traction (VMT) and implementation of 
the National Institute for Health and Care Excellence (NICE) guidance (TA297). 
Methods: A monocentric, retrospective review of consecutive patients undergoing optical 
coherence tomography (OCT) imaging over a 3 month period. Patients with VMT in at least 
one eye were identified for further data collection on laterality, visual acuity, symptoms, pres-
ence of epiretinal membrane, macular hole and treatment selection. 
Results: A total of 3472 patients underwent OCT imaging with a total of 6878 eyes scanned. 
Out of 87 patients, 74 patients had unilateral VMT (38 right, 36 left) and 13 patients had bilateral 
VMT. Eighteen patients with unilateral VMT satisfied NICE criteria of severe sight problems 
in the affected eye. Eight were managed for a coexisting pathology, one refused treatment, one 
patient did not attend, two closed spontaneously, and one received ocriplasmin prior to the 
study start date. Only two patients with unilateral VMT received ocriplasmin and three under-
went vitrectomy. Those failing to meet NICE criteria for unilateral VMT were predominantly 
asymptomatic (n=49) or had coexisting ERM (n=5) or both (n=2). 
Conclusion: Ocriplasmin provides an alternative treatment for patients with symptomatic 
VMT. Our data shows that the majority of patients with VMT do not meet NICE TA297 
primarily due to lack of symptoms. Those meeting NICE criteria, but not treated, tended to 
have coexisting macular pathology. Variation in patient selection due to subjective factors not 
outlined in NICE guidance suggests that real world outcomes of ocriplasmin therapy should 
be interpreted with caution.
Keywords: vitreomacular traction, posterior vitreous detachment, pharmacologic vitreolysis, 
ocriplasmin
Introduction
Vitreomacular traction (VMT), first described by Reese et al 1970,1 is a disorder 
widely accepted to be the result of traction at the vitreoretinal interface. This is due to 
vitreomacular adhesion (VMA) causing incomplete or anomalous detachment of the 
posterior hyaloid face from the internal limiting membrane during the physiological 
process of posterior vitreous detachment (PVD).1–6 VMA and VMT can lead to reduced 
visual acuity from distortion, displacement, or disruption of the normal foveal and 
retinal anatomy, resulting in clinically recognized lesions, such as macular pucker, focal 
cysts, foveal eversion, and macular hole (MH) formation.7–12 Until recently, observation 
or pars plana vitrectomy (PPV) were the only treatment modalities available. More 
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recently, landmark clinical trials have reported that ocriplas-
min, a recombinant truncated form of human plasmin, which 
acts by cleaving fibronectin and laminin, to be effective in 
resolution of VMT.13–16 Furthermore, recent analysis of the 
trial data shows improved patient-reported visual outcome 
following ocriplasmin compared to placebo.17 Real-world 
data has shown that VMT resolution following ocriplasmin 
varies between 42% and 50% and MH closure in 27%–50% 
of cases.18–22 Quezada-Ruiz et al have also recently reported 
favorable visual outcome in eleven of 23 patients treated for 
VMT with and without MHs, and observed that VMT release 
occurred more frequently in those with outer reflectivity 
changes that resolved following VMT release.23
The National Institute for Health and Care Excellence 
(NICE) has published guidance (TA297) on patient-selection 
criteria for ocriplasmin therapy. NICE guidance indicates that 
patients with VMT – in the absence of epiretinal membrane 
(ERM) – with a stage II full-thickness MH (FTMH) less than 
400 µm and/or severe symptoms should be offered ocriplasmin 
treatment. In the costing tool provided with TA297, the number 
of patients requiring ocriplasmin therapy per year in England 
was estimated at 745 (with MH) and 209 (without MH) for 
a population of 55 million, and 120 patients who would still 
require vitrectomy due to persistent VMT following ocriplas-
min.24 This would equate to approximately 17 patients requiring 
ocriplasmin therapy and two requiring additional vitrectomy for 
persistent VMT per year in a population of one million.
The clinical characteristics that influence the clinical 
decision-making process in selecting patients for watchful 
waiting, ocriplasmin therapy, or vitrectomy in the real world 
have not been previously studied. Variable estimates of the 
frequency and prevalence of VMT have been published, but 
the resultant actual frequency of ocriplasmin use in the real 
world and the reasons for noncompliance are not known 
either.25–27 Such quantitative and qualitative data could be 
valuable to clinicians in designing their local pathways for 
patient selection and for planning future resources to imple-
ment NICE guidance. In this study, we used a case-by-case 
tracking design to investigate the qualitative aspects in patient 
selection and the quantitative impact of disease burden in a 
real-world VMT treatment-service scenario.
Materials and methods
The setting for the study was our hospital’s retinal imaging 
department, which provides on-demand multimodal imag-
ing for patients referred from primary care services from 
a catchment population of around 850,000 to our general 
ophthalmology services, in addition to patients referred into 
our secondary and tertiary macular referral service.
In order to investigate patient-selection criteria for ocriplas-
min therapy, a period of 3 consecutive months (May, June, 
and July 2014) was chosen to allow 6 complete months after 
publication of the NICE TA297 guidance. The complete 
electronic imaging database was used to identify consecutive 
patients undergoing optical coherence tomography (OCT) 
imaging on at least one occasion over this period. Individual 
imaging episodes were easily located on a common server, 
which contained all images archived from four networked 
OCT machines (Spectralis; Heidelberg Engineering GmbH, 
Heidelberg, Germany). In cases where patients attended more 
than once during the study period, the earliest imaging episode 
was selected. The individual scans were viewed using the pro-
prietary software (Eye Explorer, Heidelberg Engineering).
Three observers (EWJP, SKA, and ISU) screened all scans 
to exclude all episodes where the posterior hyaloid line was not 
visible. All scan episodes where the posterior hyaloid line was 
distinctly visible as a line anterior to the retina and adhering 
to the macula were subsequently viewed by a senior retinal 
specialist (YCY and NN) to confirm the diagnoses of VMT 
or VMA with or without ERM and with or without an MH. 
For the patients confirmed to have VMT by the senior retinal 
specialist, case notes were then reviewed retrospectively. Data 
collected from case notes included visual acuity, symptoms, 
primary diagnosis, and subsequent management documented 
at the time of the hospital visit. Patients found to meet the 
NICE guidance were individually tracked for up to 6 months to 
determine the treatment they received and rationale for this 
treatment option. A flowchart was created to illustrate quan-
titatively the disposition in terms of management approach 
depending on eligibility according to NICE criteria and 
qualitatively the disposition in terms of factors attributed to 
patient eligibility or ineligibility (Figure 1). In line with Royal 
Wolverhampton Hospitals policy, ethics committee approval 
for retrospective data collection studies was not required. 
Patient consent is not necessary for clinical evaluation of local 
practice against current recommended guidelines.
Results
During the 3-month study period, a total of 3,472 patients 
had OCT scans, with a total of 6,878 eyes scanned. Of 
87 patients (54 females, 33 males) with an average age of 
76.2 years (range 51–96 years), 74 patients had unilateral 
VMT (38 right, 36 left) and 13 patients had bilateral VMT. 
Representative spectral domain OCT images for VMT are 
shown in Figure 1. The quantitative and qualitative disposi-
tions of these patients are shown in Figure 2.
Of 74 patients with unilateral VMT, 18 patients met 
NICE criteria for ocriplasmin and 56 did not. Of the 18 
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patients that met NICE criteria for ocriplasmin, only 
two patients actually received ocriplasmin. Three patients 
had PPV, and 13 patients had no intervention. The reasons 
given for not using ocriplasmin included 1) opted for PPV 
(n=3), 2) patient refused treatment (n=1), 3) watchful wait-
ing recommended due to improving OCT appearances 
(n=2), 4) prior ocriplasmin without success (n=1), 5) lost 
to follow-up (n=1), and 6) presence of coexisting pathology 
(n=8). Of these eight patients, three had wet age-related 
macular degeneration (AMD) and were being treated with 
ranibizumab, two were diagnosed with dry AMD with no 
follow-up, one had severe primary open-angle glaucoma 
that required trabeculectomy, one opted for cataract surgery 
only without any VMT treatment, and another was awaiting 
Figure 1 representative sD OCT images of vitreomacular traction.
Notes: (A) VMT with inner and outer retinal changes; (B) VMT with traction and cyst formation; and (C) VMT with full-thickness macular hole less than 400 µm.
Abbreviations: sD, spectral domain; OCT, optical coherence tomography; VMT, vitreomacular traction.
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Figure 2 VMT study flow. Flow diagram demonstrating the number of patients with VMT recruited into the study based on retrospective analysis of SD OCT images.
Note: *Copathology represents those patients with concurrent eye disease that was more likely to be causing their symptoms (examples include AMD and cataract).
Abbreviations: AMD, age-related macular degeneration; DNA, did not attend; ERM, epiretinal membrane; FTMH, full-thickness macular hole; LE, left eye; NICE, 
national institute for health and Care excellence; OCT, optical coherence tomography; PPV, pars plana vitrectomy; re, right eye; rx, treatment; sD, spectral domain; 
VMT, vitreomacular traction.
phacoemulsification and MH repair (Table 1). The 56 patients 
failing to meet NICE criteria with unilateral VMT were 
predominantly asymptomatic (n=49) or had coexisting ERM 
(n=5) or both (n=2).
There were 13 patients with bilateral VMT, which are 
also illustrated in Figure 1. Dispositions are shown in terms 
of study eyes and the fellow eyes, where the study eye rep-
resents the eye with the more significant disease. Among the 
study eyes, six eyes met NICE criteria and only one received 
ocriplasmin. For the remaining five eyes, one patient refused 
treatment, two had dry AMD and were not followed up, one 
was watched and felt to be stable, and lastly one patient had 
FTMH that was closing spontaneously. Among seven study 
eyes that did not meet NICE criteria, four were asymptomatic, 
one had symptomatic ERM, one had ERM without symp-
toms, and one had a symptomatic large FTMH with ERM.
Three of 13 fellow eyes met NICE criteria, and none of 
these received treatment. Two eyes had dry AMD, and one 
eye was watched and found to be stable. Ten fellow eyes did 
not meet NICE criteria, and all of these were asymptomatic. 
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Table 2 shows the distribution of treatment modality used 
for patients meeting NICE criteria. The average age of these 
patients was 75.6 years. Six patients received treatment, three 
received ocriplasmin therapy, and three underwent PPV. 
Those eyes that underwent PPV had worse visual acuities 
prior to intervention.
Discussion
There has been a paradigm shift in the management of 
patients with VMT, macular pucker, ERM, and MH. A subset 
of patients with focal VMT, without ERM formation, with an 
FTMH (less than 400 µm), and/or severe symptoms can now 
be treated with ocriplasmin therapy instead of conventional 
PPV. This new medical vitreolysis approach is supported by 
high-level evidence from large, well-designed, randomized 
clinical trials and also by recent guidance issued by NICE. 
In this study, we set out to investigate the qualitative and 
quantitative aspects of the selection process involved in iden-
tifying suitable patients for ocriplasmin therapy, in order to 
understand the frequency and numbers of patients that meet 
the strict NICE guidance criteria for vitreolysis and also the 
multitude of factors that lead to selection of alternative forms 
of management, such as PPV or watchful waiting.
The most striking finding was the high frequency of 
VMT. Within a period of 3 months in a medium-size 
department, 3,472 patients received at least one OCT scan. 
Of this number, a total of 74 patients were found to have 
unilateral VMT and another 13 patients had bilateral VMT. 
This figure is a reflection of how commonly encountered 
focal VMT is in everyday practice. Many of these patients 
have coexisting pathologies, such as AMD, which require 
monthly visits, and this can lead to a false impression of a 
higher annual incidence rate of new cases of focal VMT. 
The true incidence of new cases of focal VMT is not known, 
as there have been few longitudinal population studies per-
formed to capture the occurrence of new cases over time in 
a population. At the 20-year follow-up of the Beaver Dam 
eye study, VMT was present in 28 eyes in 24 individuals 
(1.6% of the 1,540 participants).26 Although the current 
study cannot give an accurate figure for incidence of 
VMT, assuming that each patient in our study represents a 
new case, we estimate the incidence to be approximately 
Table 1 Patients meeting NICE criteria with visual problems due to copathologies
Patient Copathology Management
1 Wet aMD + srF Ranibizumab injection(s)
2 Dry aMD and dystrophy none
3 Dry aMD + CMe none
4 Cataract Phacoemulsification (declined joint procedure with PPV)
5 Wet aMD + CnV Ranibizumab injection(s)
6 right Mh PPV and phacoemulsification
7 POag Trabeculectomy
8 Wet aMD + raP lesions Ranibizumab injection(s)
Abbreviations: AMD, age-related macular degeneration; CME, cystoid macular edema; CNV, choroidal neovascularization; MH, macular hole; NICE, National Institute for 
Health and Care Excellence; PPV, pars plana vitrectomy; POAG, primary open-angle glaucoma; RAP, retinal angiomatous proliferation; SRF, subretinal fluid.
Table 2 Treated patients meeting niCe criteria
Patient Age 
(years)
Initial VA Diagnosis Treatment Follow-up 
(days)
Postoperative 
macular status
VA on 
follow-up
a 81 6/12 left symptomatic VMT Ocriplasmin 25 Mh closed – VMT 
persists
6/12
B 73 6/12 right symptomatic VMT Ocriplasmin 115 VMT persists 6/12
C 77 6/24 left symptomatic VMT Ocriplasmin 280 VMT persists 6/18
D 59 6/120 left symptomatic VMT + FTMh PPV 147 Mh closed 6/60
e 80 6/60 left symptomatic VMT PPV 232 VMT resolved 6/60
F 75 6/36 right symptomatic VMT + FTMh PPV 89 Mh closed 6/24
average 74.2 148
Notes: Six patients underwent treatment following the study period. The average age of these patients was 74.2 years. Visual acuity appeared to be better in the ocriplasmin 
group compared to those receiving PPV. Average follow-up was 148 days after the first OCT scan. None of the patients receiving ocriplasmin had vitreous detachment at 
follow-up, although one had Mh closure. Two of two patients undergoing PPV for VMT with FTMh had macular hole closure.
Abbreviations: FTMh, full-thickness Mh (meeting niCe guidance); Mh, macular hole; niCe, national institute for health and Care excellence; PPV, pars plana vitrectomy; 
Va, visual acuity; VMT, vitreomacular traction; OCT, optical coherence tomography.
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2.5%. The comparatively high frequency of VMT in our 
study could be explained by a varying demographic. How-
ever, it could also represent the high fallout of patients in 
the Beaver Dam study (4,926 participants at baseline to 
1,540 at 20 years), which reflects survival as opposed to 
participation. Due to the asymptomatic nature of VMT as 
reflected in this study, it is likely that any study involving 
symptomatic patients will underestimate the frequency of 
disease in the population.
Another finding was that of 87 patients with focal VMT in 
one or both eyes, 63 patients were not suitable for ocriplasmin 
therapy, as they were either asymptomatic or had associ-
ated ERM. This high proportion is in keeping with previous 
reports and meta-analyses of the rates of focal VMT in the 
overall population. This finding may justify the provision of 
separate guidelines for monitoring of these patients, so that 
early cases of MH can be detected and treated more promptly 
with either vitreolysis or surgery. The large proportion of 
patients in this category may represent a future public health 
issue or burden on resources.
Of 24 patients who satisfied the NICE criteria for 
ocriplasmin, only three eyes received this treatment. The 
reasons for noncompliance with the guidance were quite 
interesting and varied. Three patients who received vitrec-
tomy typically had worse visual acuity compared to those 
treated with ocriplasmin, and these patients all opted for 
this treatment over ocriplasmin. Twelve eyes in ten patients 
were not treated, due to coexisting eye disease, in particular 
AMD of varying severity, considered the more likely cause 
for visual symptoms. The other reasons included partial or 
full resolution, patient refusal and patient nonattendance.
Our low numbers of patients treated with ocriplasmin did 
not agree with predicted figures that have been published. 
Amoaku et al predicted 10–20 patients would require treat-
ment per 100,000 per year. From our figures, using a catch-
ment population of 850,000, we estimate a frequency of 
ocriplasmin use at 1.4 per 100,000 per year.28 This discrepancy 
may well be partly due to the variation in patient selection for 
treatment and in particular the subjective interpretation of the 
definition of “symptomatic”, and what constitutes focal VMT 
on an OCT scan. Another factor may be the lack of guidance 
on coexisting macular pathology. A large proportion of cases 
of symptomatic focal VMT also had coexisting pathology. 
There may be different emphasis on the exclusion of patients 
with coexisting pathology between studies and between 
sites. Although NICE guidance does not explicitly exclude 
focal VMT with coexisting macular pathology to be treated 
with ocriplasmin, some clinicians (like ours) may still be 
excluding such patients, as they would not have been eligible 
for entry into the pivotal MIVI-TRUST (Microplasmin for 
Intravitreous Injection – Traction Release without Surgical 
Treatment) trials on which the NICE guidance was based.14 
Another potential reason for excluding patients is refractive 
error. It is well known that eyes that are highly myopic are 
at increased risk of developing retinal detachment following 
PVD, and the presence of very early VD in myopic eyes has 
been recently reported using swept-source OCT.29 Although 
we did not capture any cases with myopia as copathology in 
any of the ocriplasmin-excluded cases in the 3-month study 
period, high myopia with pathological vitreous and retinal 
changes may be an additional factor that could deter selection 
of patients for ocriplasmin therapy.
In our study, we could not capture the stage of PVD in 
those eyes with VMT, as this was not a necessary criterion 
of selection of therapy for VMT at our site. However, as 
such imaging techniques as swept-source OCT become 
more widely available, the stage of PVD may become more 
reliable, as shown recently by Itakura et al and Uchino et al, 
and will undoubtedly play a more important role in the 
decision-making process for VMT therapy.29,30
Ocriplasmin represents a valuable alternative treatment 
option for patients with symptomatic focal VMT, which has 
been found by this and many other studies to be a commonly 
encountered condition. However, the number of cases suit-
able for ocriplasmin therapy may actually be quite low, 
and the main reasons for exclusion were lack of sufficient 
symptoms and the coexistence of another macular pathology. 
These subjective factors are not covered explicitly under 
NICE criteria, and future publication of real-world outcomes 
of ocriplasmin therapy should be interpreted cautiously, as 
there may be variation in patient selection. Clinicians in other 
departments with high attrition rates due to their selection 
process for ocriplasmin therapy may find our results of cor-
roborative value. The large proportion of patients without 
significant symptoms may warrant the development of strate-
gies to monitor such patients in a cost-effective way.
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